The Promise of Combination Therapies with FOXM1 Inhibitors for Cancer Treatment
Cancers · 12.02.2024 · 16 (4) · 756
DOI: 10.3390/cancers16040756 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 12.02.2024. Verfasst von Nawal Merjaneh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ 85016, USA. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart Lung and Blood Institute, NIH.
Abstract (Originalsprache)
Forkhead box M1 (FOXM1) is a transcription factor in the forkhead (FOX) family, which is required for cellular proliferation in normal and neoplastic cells. FOXM1 is highly expressed in many different cancers, and its expression is associated with a higher tumor stage and worse patient-related outcomes. Abnormally high expression of FOXM1 in cancers compared to normal tissue makes FOXM1 an attractive target for pharmacological inhibition. FOXM1-inhibiting agents and specific FOXM1-targeted small-molecule inhibitors have been developed in the lab and some of them have shown promising efficacy and safety profiles in mouse models. While the future goal is to translate FOXM1 inhibitors to clinical trials, potential synergistic drug combinations can maximize anti-tumor efficacy while minimizing off-target side effects. Hence, we discuss the rationale and efficacy of all previously studied drug combinations with FOXM1 inhibitors for cancer therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ 85016, USA.
- Department of Child Health, Division of Hematology and Oncology, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA.
- The Columbian College of Arts and Sciences, George Washington University, Washington, DC 20052, USA.
- Phoenix Children's Research Institute, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA.
- Division of Neonatology, Phoenix Children's Hospital, Phoenix, AZ 85016, USA.
ORCID-Profile: Nawal Merjaneh
Förderung
- NHLBI NIH HHS
- National Heart Lung and Blood Institute
- NIH
Zitieren
APA
Merjaneh, N., Hajjar, M., Lan, Y. W., Kalinichenko, V. V., & Kalin, T. V. (2024). The Promise of Combination Therapies with FOXM1 Inhibitors for Cancer Treatment. Cancers, 16(4), 756. https://doi.org/10.3390/cancers16040756
Vancouver
Merjaneh N, Hajjar M, Lan YW, Kalinichenko VV, Kalin TV. The Promise of Combination Therapies with FOXM1 Inhibitors for Cancer Treatment. Cancers. 2024;16(4):756. doi:10.3390/cancers16040756
BibTeX
@article{Merjaneh2024,
author = {Merjaneh, Nawal and Hajjar, Mona and Lan, Ying-Wei and Kalinichenko, Vladimir V and Kalin, Tanya V},
title = {The Promise of Combination Therapies with FOXM1 Inhibitors for Cancer Treatment},
journal = {Cancers},
year = {2024},
volume = {16},
number = {4},
pages = {756},
doi = {10.3390/cancers16040756}
}
EUVIMED